Elena E. F.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 1a/1b Open-Label Study of IGM-8444 Monotherapy and Combination Therapy in Relapsed, Refractory, or Newly Diagnosed Colorectal Cancer
- Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Data & Insights
Has run more than one trial at 151 of 336 partner sites.
Specializations
Colorectal Cancer Specialization
Extensively involved in investigating novel therapeutic approaches for metastatic colorectal cancer, with particular focus on various genetic subtypes including BRAF V600E-mutant, KRAS/NRAS wild-type, and MSI-H/dMMR variants.
- Advanced and Metastatic Disease Management
- Targeted Therapy Development
- Immunotherapy Applications
Combination Therapy Research
Leading investigations into innovative combination treatments, including immunotherapy combinations and targeted therapy approaches with established chemotherapy regimens.
- Novel Drug Combinations
- Chemotherapy Integration
- Treatment Sequencing Strategies
Precision Medicine Applications
Focused on developing personalized treatment approaches based on molecular profiling and biomarker analysis in colorectal cancer patients.
- Biomarker-Driven Therapies
- Genetic Mutation Analysis
- Treatment Response Monitoring
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.